Anti-Inflammatory Action of Resveratrol in the Central Nervous System in Relation to Glucose Concentration-An In Vitro Study on a Blood-Brain Barrier Model

Int J Mol Sci. 2024 Mar 7;25(6):3110. doi: 10.3390/ijms25063110.

Abstract

Unbalanced blood glucose levels may cause inflammation within the central nervous system (CNS). This effect can be reversed by the action of a natural neuroprotective compound, resveratrol (RSV). The study aimed to investigate the anti-inflammatory effect of RSV on astrocyte cytokine profiles within an in vitro model of the blood-brain barrier (BBB) under varying glucose concentrations (2.2, 5.0, and 25.0 mmol/L), corresponding to hypo-, normo-, and hyperglycemia. The model included co-cultures of astrocytes (brain compartment, BC) and endothelial cells (microvascular compartment, MC), separated by 0.4 µm wide pores. Subsequent exposure to 0.2 μM LPS in the brain compartment (BC) and 50 μM RSV in the microvascular compartment (MC) of each well was carried out. Cytokine levels (IL-1 α, IL-1 β, IL-2, IL-4, IL-6, IL-8) in the BC were assessed using a Multi-Analyte ELISArray Kit before and after the addition of LPS and RSV. Statistical analysis was performed to determine significance levels. The results demonstrated that RSV reduced the concentration of all studied cytokines in the BC, regardless of glucose levels, with the most substantial decrease observed under normoglycemic conditions. Additionally, the concentration of RSV in the BC was highest under normoglycemic conditions compared to hypo- and hyperglycemia. These findings confirm that administration of RSV in the MC exerts anti-inflammatory effects within the BC, particularly under normoglycemia-simulating conditions. Further in vivo studies, including animal and human research, are warranted to elucidate the bioavailability of RSV within the central nervous system (CNS).

Keywords: anti-inflammatory action; astrocytes; blood–brain barrier; glucose; inflammatory response modulation; resveratrol.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Blood-Brain Barrier* / metabolism
  • Cytokines / metabolism
  • Endothelial Cells / metabolism
  • Glucose / pharmacology
  • Humans
  • Hyperglycemia* / drug therapy
  • Lipopolysaccharides / toxicity
  • Resveratrol / pharmacology

Substances

  • Resveratrol
  • Lipopolysaccharides
  • Anti-Inflammatory Agents
  • Cytokines
  • Glucose

Grants and funding

This research was funded by the Medical University of Warsaw (internal grants no. NZME/N/21 and NZME/N/22). It received no specific external grant from any funding agency in the public, commercial, or not-for-profit sectors.